替沙格韦单抗-西加韦单抗治疗COVID-19住院患者:一项随机、双盲、3期试验
这项随机、双盲、3期、安慰剂对照试验在美国、欧洲、乌干达和新加坡的81个中心纳入症状不超过12天且因COVID-19住院的成人,1:1随机接受静脉替沙格韦单抗300 mg-西加韦单抗300 mg或安慰剂,均加用瑞德西韦及其他标准治疗。主要终点为至第90天的持续恢复时间(出院后连续14天在家),全队列中替沙格韦单抗-西加韦单抗组第90天累积持续恢复发生率为89%,安慰剂组为86%(恢复率比RRR 1.08,95%CI 0.97-1.20;p=0.21),血清阴性亚组结果相似(RRR 1.14,95%CI 0.97-1.34;p=0.13)。死亡率方面,替沙格韦单抗-西加韦单抗组61例(9%)低于安慰剂组86例(12%)(HR 0.70,95%CI 0.50-0.97;p=0.032)。复合安全性结局在替沙格韦单抗-西加韦单抗组178例(25%)、安慰剂组212例(30%)(HR 0.83,95%CI 0.68-1.01;p=0.059),严重不良事件分别为34例(5%)和38例(5%)。
要点
- 主要终点未达标:全队列第90天持续恢复累积发生率替沙格韦单抗-西加韦单抗组89% vs 安慰剂组86%(RRR 1.08,95%CI 0.97-1.20;p=0.21)。
- 死亡率较低:替沙格韦单抗-西加韦单抗组61例(9%)vs 安慰剂组86例(12%)(HR 0.70,95%CI 0.50-0.97;p=0.032)。
- 血清阴性亚组持续恢复结果相似:RRR 1.14(95%CI 0.97-1.34;p=0.13)。
- 复合安全性结局:替沙格韦单抗-西加韦单抗组178例(25%)vs 安慰剂组212例(30%)(HR 0.83,95%CI 0.68-1.01;p=0.059)。
- 严重不良事件:替沙格韦单抗-西加韦单抗组34例(5%)vs 安慰剂组38例(5%)。
适用人群与场景
- 成人,症状持续不超过12天,因COVID-19住院,来自美国、欧洲、乌干达和新加坡的81个中心。
- 排除急性器官衰竭患者,包括接受有创机械通气、体外膜氧合、血管升压药治疗、机械循环支持或新开始肾脏替代治疗者。
处置流程与药物剂量
- 静脉给予替沙格韦单抗300 mg-西加韦单抗300 mg,单次输注,加用瑞德西韦及其他标准治疗;对照组给予安慰剂加瑞德西韦及其他标准治疗。
研究设计与关键结果
- 随机、双盲、3期、安慰剂对照试验,81个中心,1455例随机分组,改良意向治疗人群1417例接受输注(替沙格韦单抗-西加韦单抗组n=710,安慰剂组n=707)。
- 主要终点第90天持续恢复累积发生率:替沙格韦单抗-西加韦单抗组89% vs 安慰剂组86%(RRR 1.08,95%CI 0.97-1.20;p=0.21);血清阴性亚组RRR 1.14(95%CI 0.97-1.34;p=0.13)。
- 死亡率:替沙格韦单抗-西加韦单抗组61例(9%)vs 安慰剂组86例(12%)(HR 0.70,95%CI 0.50-0.97;p=0.032)。
- 复合安全性结局:替沙格韦单抗-西加韦单抗组178例(25%)vs 安慰剂组212例(30%)(HR 0.83,95%CI 0.68-1.01;p=0.059)。
- 严重不良事件:替沙格韦单抗-西加韦单抗组34例(5%)vs 安慰剂组38例(5%)。
证据类型、等级与局限
- 证据类型:随机、双盲、3期、安慰剂对照试验。
对床旁实践的改变
- 在因COVID-19住院并接受瑞德西韦及其他标准治疗的患者中,替沙格韦单抗-西加韦单抗未改善主要终点持续恢复时间,但安全性良好且死亡率较低;作者认为该结果不支持将其用于改善持续恢复。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tixagevimab-cilgavimab is a neutralising monoclonal antibody combination hypothesised to improve outcomes for patients hospitalised with COVID-19. We aimed to compare tixagevimab-cilgavimab versus placebo, in patients receiving remdesivir and other standard care.
METHODS: In a randomised, double-blind, phase 3, placebo-controlled trial, adults with symptoms for up to 12 days and hospitalised for COVID-19 at 81 sites in the USA, Europe, Uganda, and Singapore were randomly assigned in a 1:1 ratio to receive intravenous tixagevimab 300 mg-cilgavimab 300 mg or placebo, in addition to remdesivir and other standard care. Patients were excluded if they had acute organ failure including receipt of invasive mechanical ventilation, extracorporeal membrane oxygenation, vasopressor therapy, mechanical circulatory support, or new renal replacement therapy. The study drug was prepared by an unmasked pharmacist; study participants, site study staff, investigators, and clinical providers were masked to study assignment. The primary outcome was time to sustained recovery up to day 90, defined as 14 consecutive days at home after hospital discharge, with co-primary analyses for the full cohort and for participants who were neutralising antibody-negative at baseline. Efficacy and safety analyses were done in the modified intention-to-treat population, defined as participants who received a complete or partial infusion of tixagevimab-cilgavimab or placebo. This study is registered with ClinicalTrials.gov, NCT04501978 and the participant follow-up is ongoing.
FINDINGS: From Feb 10 to Sept 30, 2021, 1455 patients were randomly assigned and 1417 in the primary modified intention-to-treat population were infused with tixagevimab-cilgavimab (n=710) or placebo (n=707). The estimated cumulative incidence of sustained recovery was 89% for tixagevimab-cilgavimab and 86% for placebo group participants at day 90 in the full cohort (recovery rate ratio [RRR] 1·08 [95% CI 0·97-1·20]; p=0·21). Results were similar in the seronegative subgroup (RRR 1·14 [0·97-1·34]; p=0·13). Mortality was lower in the tixagevimab-cilgavimab group (61 [9%]) versus placebo group (86 [12%]; hazard ratio [HR] 0·70 [95% CI 0·50-0·97]; p=0·032). The composite safety outcome occurred in 178 (25%) tixagevimab-cilgavimab and 212 (30%) placebo group participants (HR 0·83 [0·68-1·01]; p=0·059). Serious adverse events occurred in 34 (5%) participants in the tixagevimab-cilgavimab group and 38 (5%) in the placebo group.
INTERPRETATION: Among patients hospitalised with COVID-19 receiving remdesivir and other standard care, tixagevimab-cilgavimab did not improve the primary outcome of time to sustained recovery but was safe and mortality was lower.
FUNDING: US National Institutes of Health (NIH) and Operation Warp Speed.
参考来源
- Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2022. PMID: 35817072. doi:10.1016/S2213-2600(22)00215-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。